Impact of Structured Diabetes Management and Knowledge Reinforcement on Clinical Outcomes in COVID-19 Patients with Type 2 Diabetes
DOI:
https://doi.org/10.61280/s1kbex80Keywords:
Diabetes Education, COVID-19 Outcomes, Glycemic Variability, Telemedicine, Elderly DiabetesAbstract
Background: Poor glycemic control is a major determinant of adverse COVID-19 outcomes. In addition to pharmacological management, patient knowledge and self-care practices influence disease trajectory.
Objective: To assess the impact of structured diabetes management combined with targeted knowledge reinforcement on glycemic control, inflammatory markers, and recovery outcomes in COVID-19 patients with T2DM.
Methods: A prospective observational study was conducted among 220 T2DM patients with confirmed COVID-19 infection. Baseline clinical, biochemical, and knowledge assessments were followed by standardized diabetes-COVID management and educational reinforcement. Pre- and post-intervention outcomes were compared.
Results: Significant improvement was observed in glycemic parameters, inflammatory markers, and patient knowledge scores. Patients with improved knowledge demonstrated better glycemic stability, reduced oxygen dependency, and faster clinical recovery.
Conclusion: Combining structured diabetes management with patient education significantly enhances COVID-19 recovery among diabetic patients. Knowledge empowerment is a critical adjunct to clinical care.
Downloads
References
1. Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546-550. doi:10.1016/S2213-8587(20)30152-2
2. Zhu L, She ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-1077.e3. doi:10.1016/j.cmet.2020.04.021
3. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021;17(1):11-30. doi:10.1038/s41574-020-00435-4
4. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8(9):782-792. doi:10.1016/S2213-8587(20)30238-2
5. Ceriello A, Standl E, Catrinoiu D, et al. Issues of diabetes management in people with diabetes and COVID-19 in ICU settings. Diabetes Care. 2020;43(7):1529-1534. doi:10.2337/dc20-1247
6. Gianchandani R, Esfandiari NH, Ang L, et al. Managing hyperglycemia in the COVID-19 inflammatory storm. Diabetes. 2020;69(10):2048-2053. doi:10.2337/dbi20-0022
7. Klonoff DC, Umpierrez GE. COVID-19 in patients with diabetes: risk factors that increase morbidity. Metabolism. 2020;108:154224. doi:10.1016/j.metabol.2020.154224
8. Khunti K, Del Prato S, Mathieu C, et al. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021;44(12):2645-2655. doi:10.2337/dc21-1318
9. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes. Lancet Diabetes Endocrinol. 2020;8(10):823-833. doi:10.1016/S2213-8587(20)30271-0
10. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes. Diabetologia. 2020;63(8):1500-1515. doi:10.1007/s00125-020-05180-x
11. Wargny M, Potier L, Gourdy P, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19. Diabetologia. 2021;64(1):1-12. doi:10.1007/s00125-020-05328-8
12. Maddaloni E, Buzzetti R. COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev. 2020;36(7):e3321. doi:10.1002/dmrr.3321
13. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: an unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513-517. doi:10.1016/j.dsx.2020.04.049
14. Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection. Diabetes Care. 2021;44(1):55-65. doi:10.2337/dc20-2155
15. Misra A, Ghosh A, Gupta R. Heterogeneity in presentation of COVID-19 in type 2 diabetes. Diabetes Metab Syndr. 2020;14(4):453-457. doi:10.1016/j.dsx.2020.04.017
16. Ghosh A, Gupta R, Misra A. Telemedicine for diabetes care in India during COVID-19 pandemic. Diabetes Metab Syndr. 2020;14(5):933-936. doi:10.1016/j.dsx.2020.06.039
17. Umpierrez GE, Klonoff DC. Diabetes technology in the inpatient setting during the COVID-19 pandemic. J Diabetes Sci Technol. 2020;14(4):795-797. doi:10.1177/1932296820935175
18. Rayman G, Lumb A, Kennon B, et al. Guidance on inpatient diabetes care during the COVID-19 pandemic. Diabet Med. 2020;37(7):1087-1089. doi:10.1111/dme.14370
19. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi:10.1016/S2213-8587(20)30272-2
20. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review. Diabetes Obes Metab. 2021;23(3):870-874. doi:10.1111/dom.14269
21. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-342. doi:10.1038/s41574-020-0364-6
22. Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis. Diabetes Metab Syndr. 2020;14(6):1563-1569. doi:10.1016/j.dsx.2020.08.015
23. Cuschieri S, Grech S. COVID-19 and diabetes: the why, the what and the how. J Diabetes Complications. 2020;34(9):107637. doi:10.1016/j.jdiacomp.2020.107637
24. Fisher L, Polonsky W, Hessler D. The importance of patient education and self-management in diabetes outcomes. Diabetes Care. 2017;40(1):104-112. doi:10.2337/dc16-0706
25. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes. Diabetes Care. 2020;43(7):1636-1649. doi:10.2337/dci20-0023
Published
Issue
Section
License
Copyright (c) 2026 Kaleem Ahmed Khan, Rakesh Kumar Jat
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Policy & Licensing terms | Tropical Journal of Pharmaceutical and Life Sciences
